--- title: "Arvinas | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 249.7 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294811520.md" datetime: "2026-08-04T11:04:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294811520.md) - [en](https://longbridge.com/en/news/294811520.md) - [zh-HK](https://longbridge.com/zh-HK/news/294811520.md) generator: "portal-rs" --- # Arvinas | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 249.7 M Revenue: As of FY2026 Q2, the actual value is USD 249.7 M, beating the estimate of USD 60.69 M. EPS: As of FY2026 Q2, the actual value is USD 2.58. EBIT: As of FY2026 Q2, the actual value is USD 169.6 M. #### Segment Revenue Arvinas, Inc. reported total revenue of $249.7 million for the second quarter of 2026, a significant increase from $22.4 million in the second quarter of 2025. For the six months ended June 30, 2026, revenue was $265.3 million, compared to $211.2 million for the same period in 2025. This increase was primarily driven by $112.6 million from the Original Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, including $126.4 million in recognized deferred revenue upon the Rigel License Agreement, $62.5 million from the Rigel License Agreement, and a $50.0 million development milestone payment for VEPPANU’s FDA approval. #### Cost of License Revenue Cost of license revenue was $9.0 million for the second quarter of 2026, up from zero in the second quarter of 2025. This increase was due to expenses under the Amended Yale License Agreement related to VEPPANU’s FDA approval and the Rigel License Agreement. #### Research and Development (R&D) Expenses GAAP R&D expenses decreased to $52.6 million in the second quarter of 2026, from $68.6 million in the prior year’s second quarter, representing a $16.0 million decrease. Non-GAAP R&D expenses were $51.4 million for the second quarter of 2026, compared to $59.5 million for the same period in 2025. #### General and Administrative (G&A) Expenses GAAP G&A expenses were $24.0 million for the second quarter of 2026, a decrease from $25.3 million in the second quarter of 2025, which was a $1.3 million decrease. Non-GAAP G&A expenses were $18.4 million for the second quarter of 2026, compared to $18.1 million for the same period in 2025. #### Income (Loss) from Operations Arvinas, Inc. reported income from operations of $164.1 million for the second quarter of 2026, a significant improvement from a loss of - $71.5 million in the second quarter of 2025. For the six months ended June 30, 2026, income from operations was $100.3 million, compared to a loss of - $0.1 million for the same period in 2025. #### Net Income (Loss) Net income for the second quarter of 2026 was $169.4 million, a substantial increase from a net loss of - $61.2 million in the second quarter of 2025. For the six months ended June 30, 2026, net income was $111.8 million, compared to $21.7 million for the same period in 2025. #### Cash, Cash Equivalents, and Marketable Securities As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $567.9 million, down from $685.4 million as of December 31, 2025. The $117.5 million decrease for the six months ended June 30, 2026, was primarily due to cash used in operations of $114.3 million (net of $35.0 million received from the Rigel License Agreement), unrealized losses on marketable securities of $2.0 million, and $1.5 million for the purchase of lab equipment and leasehold improvements. #### Operational Highlights Arvinas, Inc. secured the first-ever regulatory approval for a PROTAC, VEPPANU, and successfully out-licensed it to Rigel Pharmaceuticals. The company also presented promising preclinical data for its HPK1 degrader program (ARV-6723) and a novel pan-KRAS degrader. #### Outlook and Guidance Arvinas, Inc. anticipates sharing clinical data from three Phase 1 programs (ARV-393, ARV-102, and ARV-027) over the next 12 months and plans to initiate its first immuno-oncology Phase 1 trial with ARV-6723 in the third quarter of 2026. The company expects to share initial data from the ARV-806 Phase 1 monotherapy dose escalation clinical trial in the second half of 2026 and plans to seek an out-licensing agreement for further ARV-806 clinical trials. Based on its current operating plan, Arvinas, Inc. believes its cash, cash equivalents, and marketable securities are sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028. ### Related Stocks - [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md) ## Related News & Research - [Arvinas' (ARVN) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company](https://longbridge.com/en/news/294856225.md) - [The protein-shredding revolution: Why Arvinas gave away the keys to its historic FDA approval](https://longbridge.com/en/news/291659953.md) - [Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan](https://longbridge.com/en/news/294880787.md) - [Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology](https://longbridge.com/en/news/295231676.md) - [Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing](https://longbridge.com/en/news/288478483.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**